Nanostructured lipid carriers-containing anticancer compounds: Preparation, characterization, and cytotoxicity studies

被引:56
作者
Bondi, Maria Luisa
Craparo, Emanuela Fabiola
Giammona, Gaetano
Cervello, Melchiorre
Azzolina, Antonina
Diana, Patrizia
Martorana, Anna
Cirrincione, Girolatno
机构
[1] CNR, Ist Studio Mat Nanostrutturati, Sez Palermo, I-90146 Palermo, Italy
[2] CNR, Ist Biomed & Immunol Mol Alberto Monriy, I-90146 Palermo, Italy
[3] Univ Palermo, Dipartimento Chim & Tecnol Farmaceut, I-90133 Palermo, Italy
[4] Univ Palermo, Dipartimento Farmacochim Tossicol & Biol, I-90133 Palermo, Italy
关键词
antitumor drugs; controlled release; human hepatocellular carcinoma cells; human prostate carcinoma cells; nanostructured lipid carrier;
D O I
10.1080/10717540600739914
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This article describes the development of nanostructured lipid carriers (NLC) as colloidal carriers for two antitumor compounds that possess a remarkable antineoplastic activity. But their limited stability and low solubility in water could give a very low parenteral bioavailability. Results revealed an enhancement of the cytotoxicity effect of drug-loaded NLC on human prostate cancer (PC-3) and human hepatocellular carcinoma (HuH-6, HuH-7) cell lines with respect to that of both free drugs. Results of characterization studies strongly support the potential application of these drugs-loaded NLC as prolonged delivery systems for lipophilic drugs by several administration routes, in particular for intravenous administration.
引用
收藏
页码:61 / 67
页数:7
相关论文
共 25 条
[11]   Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review [J].
Maeda, H ;
Wu, J ;
Sawa, T ;
Matsumura, Y ;
Hori, K .
JOURNAL OF CONTROLLED RELEASE, 2000, 65 (1-2) :271-284
[12]   Solid lipid nanoparticles -: Production, characterization and applications [J].
Mehnert, W ;
Mäder, K .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 47 (2-3) :165-196
[13]   Antitumor characteristics of methoxypolyethylene glycol-poly(DL-lactic acid) nanoparticles containing camptothecin [J].
Miura, H ;
Onishi, H ;
Sasatsu, M ;
Machida, Y .
JOURNAL OF CONTROLLED RELEASE, 2004, 97 (01) :101-113
[14]   FEASIBILITY OF A HIGH-FLUX ANTICANCER DRUG SCREEN USING A DIVERSE PANEL OF CULTURED HUMAN TUMOR-CELL LINES [J].
MONKS, A ;
SCUDIERO, D ;
SKEHAN, P ;
SHOEMAKER, R ;
PAULL, K ;
VISTICA, D ;
HOSE, C ;
LANGLEY, J ;
CRONISE, P ;
VAIGROWOLFF, A ;
GRAYGOODRICH, M ;
CAMPBELL, H ;
MAYO, J ;
BOYD, M .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (11) :757-766
[15]   Nanostructured lipid matrices for improved microencapsulation of drugs [J].
Müller, RH ;
Radtke, M ;
Wissing, SA .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 242 (1-2) :121-128
[16]   Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations [J].
Müller, RH ;
Radtke, M ;
Wissing, SA .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 :S131-S155
[17]   Solid lipid nanoparticles (SLN) for controlled drug delivery -: a review of the state of the art [J].
Müller, RH ;
Mäder, K ;
Gohla, S .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2000, 50 (01) :161-177
[18]   Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues [J].
Noguchi, Y ;
Wu, J ;
Duncan, R ;
Strohalm, J ;
Ulbrich, K ;
Akaike, T ;
Maeda, H .
JAPANESE JOURNAL OF CANCER RESEARCH, 1998, 89 (03) :307-314
[19]  
Plowman J, 1997, ANTICANCER DRUG DEV, P101
[20]  
RADTKE M, 2001, NEW DRUGS, V2, P97